Orchid Pharma profit and loss

Latest FY26

Revenue: ₹1,233cr+33.7% on FY25
EBITDA: ₹33.6cr−71.3% on FY25
Net profit: ₹10.0cr−90.0% on FY25
EPS: ₹1.66−91.6% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	1,073	1,233	922	819	666	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	26.0	36.4	27.5	30.9	19.4
	1,099	1,269	949	850	685
	647	771	585	528	406
	1.5	1.7	2.6	0.0	0.0
	76.4	71.4	−43.9	−43.9	−21.5
	105	118	86.4	69.6	65.4
	11.1	9.0	14.5	16.4	32.2
	39.8	43.2	34.5	33.2	54.8
	199	237	174	155	132
	1,080	1,251	854	758	669
	44.2	33.6	117	111	83.6
	4.5	−9.7	82.6	77.4	28.8
Profit
	19.3	17.8	95.6	91.9	16.0
	−7.3	−7.3	0.0	0.0	39.2
	12.0	10.4	95.6	91.9	55.2
	0.0	0.0	0.0	0.1	0.0
	0.1	−0.2	−0.2	−3.2	0.0
	0.1	−0.2	−0.2	−3.1	0.0
	−1.2	−0.7	3.9	−2.9	−2.2
	10.7	10.0	99.7	92.2	46.3
	11.9	10.6	95.8	95.1	55.2
	0.0	0.0	0.0	0.0	−6.8
	1.5	1.3	−0.8	−0.3	−0.2
	12.2	11.3	98.9	91.8	46.1
	—	—	—	—	46.3
Per share
	₹1.23	₹1.66	₹19.65	₹19.06	₹11.35
	₹1.23	₹1.66	₹19.65	₹19.06	₹11.35
Revenue detail — as filed
	—	13.2	0.0	2.9	2.2
Continuing & discontinued operations
	0.0	0.0	0.0	0.0	−6.8
Other comprehensive income — detail
	1.5	1.3	−0.8	—	—
	1.5	1.3	−0.8	−0.3	—
	—	—	—	0.0	0.2
	—	—	—	—	46.3
Per share — as-filed variants
	₹1.23	₹1.66	₹19.65	₹19.06	₹13.01
	₹1.23	₹1.66	₹19.65	₹19.06	₹13.01
	₹0.00	₹0.00	₹0.00	₹0.00	−₹1.66
	₹0.00	₹0.00	₹0.00	₹0.00	−₹1.66
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	348	388	378	335	281
	32.4%	31.5%	41.0%	40.9%	42.2%
Adjusted (ex-exceptional items) — derived
	19.3	17.8	95.6	91.9	16.0
	−7.3	−7.3	0.0	0.0	39.2
	18.0	17.3	99.7	92.2	7.1
	₹2.07	₹2.88	₹19.65	₹19.06	₹1.74

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ORCHPHARMA₹865.00

Orchid Pharma Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersFDC GUJTHEM IOLCP MOREPENLAB RPGLIFE GUFICBIO INNOVACAP UNICHEMLABMcap ₹5,180 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	665.9	819.4	921.9	1,232.8	1,073.3
Other Income	19.4	30.9	27.5	36.4	26.0
Total Income	685.3	850.2	949.4	1,269.2	1,099.3
Expenses
+ Cost of Materials Consumed	406.1	528.4	585.5	771.4	647.5
+ Purchases of Stock-in-Trade	0.0	0.0	2.6	1.7	1.5
+ Changes in Inventories	-21.5	-43.9	-43.9	71.4	76.4
+ Employee Benefit Expense	65.4	69.6	86.4	117.7	104.6
+ Finance Costs	32.2	16.4	14.5	9.0	11.1
+ Depreciation & Amortisation	54.8	33.2	34.5	43.2	39.8
+ Other Expenses	132.3	154.6	174.2	237.1	199.0
Total Expenses	669.3	758.3	853.8	1,251.4	1,079.9
EBITDA	83.6	110.7	117.2	33.6	44.2
EBIT	28.8	77.4	82.6	-9.7	4.5
Profit
PBT before Exceptional Items	16.0	91.9	95.6	17.8	19.3
+ Exceptional Items	39.2	0.0	0.0	-7.3	-7.3
Pretax Income	55.2	91.9	95.6	10.4	12.0
+ Current Tax	0.0	0.1	0.0	0.0	0.0
+ Deferred Tax	0.0	-3.2	-0.2	-0.2	0.1
Tax Expense	0.0	-3.1	-0.2	-0.2	0.1
+ Share of Associates & JVs	-2.2	-2.9	3.9	-0.7	-1.2
Net Income	46.3	92.2	99.7	10.0	10.7
+ Net Income — Continuing Ops	55.2	95.1	95.8	10.6	11.9
+ Net Income — Discontinued Ops	-6.8	0.0	0.0	0.0	0.0
+ Other Comprehensive Income	-0.2	-0.3	-0.8	1.3	1.5
Total Comprehensive Income	46.1	91.8	98.9	11.3	12.2
Net Income to Common	46.3	—	—	—	—
Per Share
Basic EPS	11.35	19.06	19.65	1.66	1.23
Diluted EPS	11.35	19.06	19.65	1.66	1.23
Revenue Detail — as filed
+ Share of P&L — Partnership Firms / LLPs	2.2	2.9	0.0	13.2	—
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax	-6.8	0.0	0.0	0.0	0.0
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-0.8	1.3	1.5
+ Items NOT to be Reclassified to P&L	—	-0.3	-0.8	1.3	1.5
+ Tax on Items NOT to be Reclassified — alt tag	0.2	0.0	—	—	—
Comprehensive Income — Owners of Parent	46.3	—	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	13.01	19.06	19.65	1.66	1.23
Diluted EPS — Continuing Operations	13.01	19.06	19.65	1.66	1.23
Basic EPS — Discontinued Operations	-1.66	0.00	0.00	0.00	0.00
Diluted EPS — Discontinued Operations	-1.66	0.00	0.00	0.00	0.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	281.3	334.9	377.7	388.3	347.9
Gross Margin %	42.24	40.87	40.97	31.50	32.41
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	16.0	91.9	95.6	17.8	19.3
− Exceptional Items (reconciliation)	39.2	0.0	0.0	-7.3	-7.3
Net Income Adj (tax-effected)	7.1	92.2	99.7	17.3	18.0
EPS Adj	1.74	19.06	19.65	2.88	2.07
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	40.8	50.7	50.7	59.9	59.9

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.